Athos Capital’s Blueprint Medicines BPMC Stock Holding History

Athos Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$2.56M	–	35
2025 Q2	$2.56M	Buy	+20,000	New	+$2.08M	3.83%	15

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Athos Capital's BPMC Position: Q3 2025 in Review

Athos Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 20,000 shares — an estimated $2.56M sold.

Athos Capital first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $2.56M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Athos Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Athos Capital sold 20,000 Blueprint Medicines shares in Q3 2025, an estimated $2.56M.
Athos Capital first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Athos Capital's Blueprint Medicines position peaked at $2.56M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Athos Capital's 13F filing for Q3 2025, filed 13 Nov 2025.